Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Collegium Pharmaceutical ( (COLL) ) is now available.
On May 14, 2026, Collegium Pharmaceutical, Inc. held its 2026 Annual Meeting of Shareholders, with 29,210,926 of 32,406,969 eligible shares represented in person or by proxy. Shareholders elected eight directors, including Rita Balice-Gordon and Garen Bohlin, to serve until the 2027 Annual Meeting, signalling continued support for the current board composition.
Investors also approved on an advisory basis the compensation of the company’s named executive officers, reflecting shareholder alignment with Collegium’s pay practices. In addition, shareholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, reinforcing continuity in the company’s financial oversight and governance structure.
The most recent analyst rating on (COLL) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Collegium Pharmaceutical stock, see the COLL Stock Forecast page.
Spark’s Take on COLL Stock
According to Spark, TipRanks’ AI Analyst, COLL is a Outperform.
The score is driven primarily by strong cash-flow-led financial performance and solid profitability, supported by constructive earnings messaging and raised guidance tied to the AZSTARYS acquisition. The main constraints are balance-sheet leverage (and incremental acquisition financing) plus a mixed technical trend with the stock still below longer-term moving averages.
To see Spark’s full report on COLL stock, click here.
More about Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing and commercializing medications, particularly in pain management. The company operates in the biopharmaceutical industry, marketing prescription therapies aimed at treating serious medical conditions for patients in the U.S. healthcare market.
Average Trading Volume: 543,890
Technical Sentiment Signal: Hold
Current Market Cap: $1.13B
For a thorough assessment of COLL stock, go to TipRanks’ Stock Analysis page.